Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE)

Tipranks - Tipranks - Tue Mar 31, 6:41AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Intensity Therapeutics, Inc. (INTS)

Alliance Global Partners analyst Matthew Venezia reiterated a Buy rating on Intensity Therapeutics, Inc. today and set a price target of $30.00. The company’s shares closed last Friday at $6.03.

According to TipRanks.com, Venezia is ranked #983 out of 12128 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intensity Therapeutics, Inc. with a $30.00 average price target.

See today’s best-performing stocks on TipRanks >>

IQVIA Holdings (IQV)

Truist Financial analyst Jailendra Singh maintained a Buy rating on IQVIA Holdings today. The company’s shares closed last Friday at $163.85.

According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of -16.4% and a 29.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

Currently, the analyst consensus on IQVIA Holdings is a Strong Buy with an average price target of $227.62, representing a 35.8% upside. In a report issued on March 15, TipRanks – PerPlexity also upgraded the stock to Buy with a $190.00 price target.

Xenon (XENE)

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Xenon, with a price target of $74.00. The company’s shares closed last Friday at $54.48.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 17.3% and a 48.1% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., Rapport Therapeutics, Inc., and Praxis Precision Medicines. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $75.82 average price target, implying a 36.8% upside from current levels. In a report issued on March 16, Wedbush also maintained a Buy rating on the stock with a $63.00 price target.

Read More on INTS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).